Translumina leaders inaugurate the local office in UAE
Translumina Therapeutics, India’s largest domestic player in the coronary stents market, announces the initiation of direct operations in the UAE
Interim Analysis of the Protégé Paclitaxel-Eluting Balloon in Real-World Practice (PEARL) Registry.
Vlieger S., Cheng J.M., et.al. Clinical Cardiology and Cardiovascular Interventions, 4(3); Doi:10.31579/2641-0419/133
Clinical Performance of a Paclitaxel Drug-Coated Balloon in Real-World Percutaneous Coronary Intervention Practice: The PEARL Registry.
Vlieger S., Cheng J.M., et al. J INVASIVE CARDIOL 2022;34(6):E462-E468
Upper Extremity Function following Transradial Percutaneous Coronary Intervention: Results of the ARCUS Trial.
Zwaan E.M., Cheung E.S., et.al. J Interv Cardiol. 2022; 2022: 6858962.
Translumina & Everstone’s Senior management team with Shareholders of Blue Medical Devices - Wellinq Group Company
Translumina further strengthens Its technology portfolio with acquisition of Blue Medical Devices, Netherlands
The acquisition gives access to a patented, innovative, and proven next-generation Drug Coated Balloon (DCB) technology that may revolutionize the scope of complex coronary interventions
